WMT

106.75

-0.25%↓

COST

941.99

-0.2%↓

PEP

151.56

-0.93%↓

KR

68.65

+0.12%↑

TGT

94.21

+0.19%↑

WMT

106.75

-0.25%↓

COST

941.99

-0.2%↓

PEP

151.56

-0.93%↓

KR

68.65

+0.12%↑

TGT

94.21

+0.19%↑

WMT

106.75

-0.25%↓

COST

941.99

-0.2%↓

PEP

151.56

-0.93%↓

KR

68.65

+0.12%↑

TGT

94.21

+0.19%↑

WMT

106.75

-0.25%↓

COST

941.99

-0.2%↓

PEP

151.56

-0.93%↓

KR

68.65

+0.12%↑

TGT

94.21

+0.19%↑

WMT

106.75

-0.25%↓

COST

941.99

-0.2%↓

PEP

151.56

-0.93%↓

KR

68.65

+0.12%↑

TGT

94.21

+0.19%↑

Search

Hims & Hers Health Inc

Gesloten

SectorConsumenten defensie

48.46 2.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

46.87

Max

48.57

Belangrijke statistieken

By Trading Economics

Inkomsten

-7M

43M

Verkoop

-41M

545M

K/W

Sectorgemiddelde

65.013

29.527

Winstmarge

7.801

Werknemers

1,637

EBITDA

-29M

37M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+0.79% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.9B

11B

Vorige openingsprijs

46.31

Vorige sluitingsprijs

48.46

Nieuwssentiment

By Acuity

50%

50%

67 / 148 Rangschikking in Consumer defensive

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Hims & Hers Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 00:05 UTC

Populaire aandelen

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29 apr 2025, 12:54 UTC

Belangrijke Marktbewegers

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 apr 2025, 23:15 UTC

Belangrijke Marktbewegers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

Belangrijke Marktbewegers

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

22 okt 2025, 21:25 UTC

Winsten

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

5 aug 2025, 20:44 UTC

Winsten

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 18:17 UTC

Winsten

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 17:26 UTC

Winsten
Acquisities, Fusies, Overnames

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 aug 2025, 15:25 UTC

Winsten

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 aug 2025, 11:27 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:55 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:36 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29 jul 2025, 16:55 UTC

Winsten

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24 jun 2025, 10:26 UTC

Marktinformatie

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3 jun 2025, 15:03 UTC

Acquisities, Fusies, Overnames

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7 mei 2025, 13:56 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 mei 2025, 14:24 UTC

Winsten

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 apr 2025, 09:30 UTC

Top Nieuws

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 apr 2025, 16:53 UTC

Top Nieuws

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mrt 2025, 15:54 UTC

Top Nieuws

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Winsten

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Top Nieuws

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dec 2024, 17:16 UTC

Top Nieuws

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dec 2024, 15:14 UTC

Top Nieuws

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dec 2024, 15:02 UTC

Top Nieuws

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dec 2024, 13:47 UTC

Top Nieuws

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dec 2024, 07:00 UTC

Top Nieuws

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

Peer Vergelijking

Prijswijziging

Hims & Hers Health Inc Prognose

Koersdoel

By TipRanks

0.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 49.75 USD  0.79%

Hoogste 85 USD

Laagste 28 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hims & Hers Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

12 ratings

2

Buy

8

Hold

2

Sell

Technische score

By Trading Central

36.685 / 52.35Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

67 / 148 Rangschikking in Consumenten defensie

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
help-icon Live chat